Age, years | |
Mean ± SD | 65.5 ± 6.7 |
Median (range) | 66.0 (43.0–81.0) |
PSA, ng/mL | |
Mean ± SD | 5.93 ± 3.07 |
Median (range) | 5.09 (0.34–14.95) |
Tumor focality | |
Unifocal | 301 (39.5%) |
Multifocal | 461 (60.5%) |
Tumor laterality | |
Unilateral unifocal | 111 (14.6%) |
Unilateral multifocal | 26 (3.4%) |
Bilateral unifocal | 190 (24.9%) |
Bilateral multifocal | 435 (57.1%) |
Overall tumor volume, ml | |
Mean ± SD | 3.24 ± 4.16 |
Median (range) | 1.97 (0.01–57.41) |
Gleason score | |
6 (3 + 3) | 86 (11.3%) |
7 (3 + 4) | 434 (57.0%) |
7 (4 + 3) | 140 (18.4%) |
8 | 35 (4.6%) |
9 | 67 (8.8%) |
Pathologic stage | |
pT2a-b | 102 (13.4%) |
pT2c | 457 (60.0%) |
pT3a | 133 (17.5%) |
pT3b | 69 (9.1%) |
pT4 | 1 (0.1%) |